Item 3. Quantitative and Qualitative Disclosures About Market Risk
ITEM 3.
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in our quantitative and qualitative market risks since July 30, 2021. For a discussion of the Company’s exposure to market risk, refer to the Company’s market
risk disclosures set forth in Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” of the 2021 Form 10-K.
Interest Rate Risk . We have interest rate risk relative to our outstanding borrowings under our revolving credit facility. At January 28, 2022, our
outstanding borrowings totaled $35,000 under our revolving credit facility (see Note 4 to the Condensed Consolidated Financial Statements). Loans under the 2019 Revolving Credit Facility bear interest, at our election, either at the prime rate
or LIBOR plus a percentage point spread based on certain specified financial ratios. Our policy has been to manage interest cost using a mix of fixed and variable rate debt (see Note 4 to our Condensed Consolidated Financial Statements). In the
fourth quarter of 2021, we issued and sold the Notes, which bear cash interest at a fixed rate of 0.625% per annum.
The impact of a one-percentage point increase or decrease in the $35,000 of our outstanding borrowings under our revolving credit facility is approximately $350 on a pre-tax annualized basis.
Credit Risk. In the fourth quarter of 2021, the Company issued the Notes and entered into the Convertible Note Hedge Transactions and the Warrant
Transactions with the Hedge Counterparties. Subject to the changes in the market price of the Company’s common stock price, the Company could be exposed to credit risk arising out of the net settlement of the Convertible Note Hedge Transactions
and the Warrant Transactions in its favor. Based on the Company’s review of the possible net settlements and the creditworthiness of the Hedge Counterparties and their affiliates, the Company believes it does not have a material exposure to
credit risk as a result of these transactions at this time.
ITEM 4.
Controls and Procedures
Our management, including our principal executive and principal financial officers, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) promulgated under the Exchange Act) as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that as of January 28, 2022, our disclosure
controls and procedures were effective for the purposes set forth in the definition thereof in Exchange Act Rule 13a-15(e).
There have been no changes (including corrective actions with regard to significant deficiencies and material weaknesses) during the quarter ended January 28, 2022 in our internal control over
financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1A.
Risk Factors
There have been no material changes in the risk factors previously disclosed in “Item 1A. Risk Factors” of our 2021 Form 10-K.
ITEM 2.
Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
There were no equity securities sold by the Company during the period covered by this Form 10-Q that were not registered under the Securities Act of 1933, amended.
30
Index
Issuer Purchases of Equity Securities
The following table sets forth information with respect to purchases of shares of the Company’s common stock made during the quarter ended January 28, 2022 by or on behalf of the Company or any
“affiliated purchaser,” as defined by Rule 10b-18(a)(3) of the Exchange Act.
Period
Total Number
of Shares
Purchased
Average Price
Paid Per
Share (1)
Total Number of
Shares
Purchased as
Part of Publicly
Announced
Plans or
Programs
Maximum Number of
Shares (or Approximate
Dollar Value) that May
Yet Be Purchased
Under the Plans or
Programs
10/30/21 – 11/26/21
7,442
$
126.42
7,442
Indeterminate (2)
11/27/21 – 12/24/21
226,878
$
123.41
226,878
Indeterminate (2)
12/25/21 – 1/28/22
45,344
$
116.69
45,344
Indeterminate (2)
Total for the quarter
279,664
$
122.40
279,664
Indeterminate (2)
(1)
Average price paid per share is calculated on a settlement basis.
(2)
On September 15, 2021, our Board of Directors approved the repurchase of up to $100,000 of our common stock, with such authorization to expire on October 7, 2022, to the extent it remains unused.
Repurchases are subject to prevailing market prices, may be made in open market or private transactions and may occur or be discontinued at any time. There can be no assurance that we will repurchase any shares.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.